Eli Lilly takes on Pfizer, Novartis with new breast cancer drug data

Eli Lilly staked its claim for a slice of sales in a new class of breast cancer drugs on Sunday as clinical data showed adding its medicine abemaciclib to standard therapy reduced the risk of disease progression by 46 percent.
Experts at the European Society for Medical Oncology (ESMO) congress in Madrid said the experimental drug's efficacy was comparable to that of rival drugs from Pfizer and Novartis already on the market.
Abemaciclib, like Pfizer's Ibrance and Novartis's Kisqali, belongs to a class of oral medicines called CDK 4/6 inhibitors that block cancer cells' ability to divide and proliferate.
Adding abemaciclib to standard endocrine therapy led to significant tumour shrinkage in 59 percent of patients compared with 44 percent in those on endocrine drugs alone in the ongoing study dubbed Monarch-3.
For the study's main goal of progression-free survival (PFS), women who only received endocrine therapy of letrozole or anastrazole on average went 14.7 months before disease worsening.
Not enough patients on abemaciclib had seen their disease worsen after 18 months of treatment to calculate median PFS for this group.
Evandro de Azambuja, a breast cancer expert at the Jules Bordet Institute, who was not involved in the study, said the rival drugs from Lilly, Pfizer and Novartis all appeared "quite similar" in terms of efficacy.
"I don't think there is a preferred drug at this moment. It will depend on availability in different countries and also cost," he told reporters in Madrid.
Abemaciclib is given continuously rather than the on-and-off cycles used for its approved rivals as it does not cause as high rates of neutropenia, a suppression of white blood cells that can lead to infection. It does, however, cause more diarrhoea.
Angelo Di Leo of Italy's Istituto Toscano Tumori, who presented the Monarch-3 findings, said the choice of which CDK 4/6 drug to use would depend on individual patients' needs.
Pfizer's Ibrance, which was first to market, is currently the market leader, ahead of Kisqali, but industry analysts forecast the new Lilly drug will reach annual sales of $1.8 billion by 2023, according to Thomson Reuters data.
Di Leo said there was substantial benefit from abemaciclib in patients with particularly challenging metastases, such as tumours in the liver or lungs. However, patients with bone metastases had a good prognosis with endocrine therapy alone.
Monarch-3 enrolled 493 post-menopausal women who had not yet received systemic treatment for advanced breast cancer that had spread.
Five patients, or about 2 percent, who received abemaciclib experienced complete responses, meaning no detectable cancer, a number that could rise.
"The longer you're on (these drugs) the greater the chance that you can have complete responses," said Matthew Goetz of the Mayo Clinic, another investigator on the study.
"This trial gives us full confirmation that CDK 4/6 inhibitors are here to stay. They're a new standard of care for breast cancer."
Source:http://www.dnaindia.com/health/report-eli-lilly-takes-on-pfizer-novartis-with-new-breast-cancer-drug-data-2544428

Comments

Post a Comment

Popular posts from this blog

EMA validates Incyte’s MAA for retifanlimab to treat metastatic squamous cell anal carcinoma

Incyte, global biopharmaceutical company, announced the validation of the Company’s Marketing Authorization Application (MAA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell anal carcinoma (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy. The European Medicines Agency’s (EMA) validation of the MAA confirms that the submission is sufficiently complete to begin the formal review process. “While the incidence of SCAC is increasing in Europe, treatment options for advanced disease are limited in their effectiveness, and there are no approved options once patients have progressed on standard therapy,” said Lance Leopold, M.D., Group vice president, Immuno-Oncology Clinical Development, Incyte. “The EMA validation of the MAA for retifanlimab – which follows the recent US Food & Drug Administration acceptance of our Biologics License Application for Priority R
Read more

Merck’s Keytruda plus platinum- and fluoropyrimidine-based chemotherapy receives US FDA nod to treat certain patients with locally advanced/metastatic esophageal or GEJ carcinoma

Merck, known as MSD outside the United States and Canada, announced that the US Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation in combination with platinum- and fluoropyrimidine-based chemotherapy. The approval is based on results from the phase 3 KEYNOTE-590 trial, which demonstrated significant improvements in overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) for Keytruda plus fluorouracil (FU) and cisplatin versus FU and cisplatin alone, regardless of histology or PD-L1 expression status. For OS and PFS, Keytruda plus FU and cisplatin reduced the risk of death by 27% (HR=0.73 [95% CI, 0.62-0.86]; p<0.0001) and reduced the risk of disease progression or death
Read more

Tumour-targeting drug paves way for bone cancer treatment

 The treatment of osteosarcoma, the most common tumour of bone, is challenging, but a new study is offering hope to the patients with this disease. The study led by The University of  Texas MD Anderson Cancer Centre  found that a drug, known as bone metastasis-targeting peptidomimetic (BMTP-11), has potential as a new therapeutic strategy for this devastating illness. Results from the preclinical study looked at BMTP-11 alone and in combination with the chemotherapy agent gemcitabine. Although osteosarcoma is a relatively rare cancer, it is a leading disease-related cause of death in children and young adults ages 10 to 20. However, over the last 25 years, the five-year survival rate has remained unchanged, and the treatment options for these patients are few. In addition, the side effects of available treatment options often are significant and cumulative, and may cause other health problems and damage to major organs. "What's novel about this treatment is that BMTP
Read more